Human papillomavirus infection

Asia Pacific Human Papillomavirus Vaccine Market Report 2022: Growing Number of HPV Awareness Programs Presents Opportunities for Growth - ResearchAndMarkets.com

Retrieved on: 
星期三, 十一月 2, 2022
Health, Pharmaceutical, BD, Human papillomavirus infection, Center for Urban and Regional Analysis, Biomarker, Cancer, Research, Hospital, Risk, COVID-19, Disease, HPV, Public health, CAGR, Technology, Wart, Woman, Cervical cancer, Laboratory, Vaccine, Dose, Application

Further, in September 2020, drug administrations across the region approved the expanded use of F. Hoffmann-La Roche Ltd, CINtec PLUS Cytology, the first triage test based on biomarker technology for women whose cervical cancer screening results are positive for high-risk types of human papillomavirus (HPV). The CINtec PLUS Cytology test identifies the simultaneous presence of the two biomarkers -- p16 and Ki-67 in a single cell. This abnormality is associated with HPV infections that progress to pre-cancer or cancer if not treated. A positive result of these two biomarkers is more significantly at risk for disease. Such robust developments in HPV diagnostics tests are likely to reshape the HPV vaccines market during the forecast period.

Key Points: 
  • The APAC human papillomavirus (HPV) vaccine market is expected to grow at a good CAGR during the forecast period.
  • The APAC human papillomavirus (HPV) vaccine market is segmented based on type, dosage, age, application, end user, and country.
  • Based on type, the APAC human papillomavirus (HPV) vaccine market is segmented into 9-valent HPV vaccine, quadrivalent HPV vaccine, and bivalent HPV vaccine.
  • Based on country, the APAC human papillomavirus (HPV) vaccine market has been categorized into China, Japan, India, Australia, Southeast Asia, New Zealand, South Korea, and the Rest of APAC.

Kovina Therapeutics Receives NIH Grant to Develop Human Papillomavirus E6 Inhibitors to Treat Oropharyngeal Cancers

Retrieved on: 
星期二, 十一月 1, 2022
Health, Infectious Diseases, Research, Pharmaceutical, Science, Biotechnology, Survival, CEO, Human papillomavirus infection, HPV-positive oropharyngeal cancer, Research, National Institute of Dental and Craniofacial Research, National Institute, NIH, Disease, Head, HPV, Oropharyngeal cancer, Incidence, NIDCR, Cancer, Therapy, Profile, SBIR, CSO, Biotechnology, Science, Small Business Innovation Research, Pharmaceutical industry, Vaccine

Kovina Therapeutics Inc. announced receipt of a Small Business Innovation Research (SBIR) one-year Phase I award from the National Institute of Dental and Craniofacial Research (NIDCR/NIH) to treat oropharyngeal cancers caused by Human Papillomavirus (HPV) infections.

Key Points: 
  • Kovina Therapeutics Inc. announced receipt of a Small Business Innovation Research (SBIR) one-year Phase I award from the National Institute of Dental and Craniofacial Research (NIDCR/NIH) to treat oropharyngeal cancers caused by Human Papillomavirus (HPV) infections.
  • Oropharyngeal cancers arising from HPV infections are increasing across many age groups and around the world.
  • This SBIR grant funds testing of our novel HPV inhibitory compounds for activity in preclinical models of oropharyngeal cancer.
  • Kovina Therapeutics is a biotechnology company developing first-in-class antiviral therapies to treat cancers and premalignant infections caused by Human Papillomavirus (HPV).

Pervistop®, the once-daily supplement specifically designed to manage persistent HPV, is now available for exclusive distribution rights worldwide.

Retrieved on: 
星期二, 十一月 1, 2022
Marketing, EGCG, United Nations Foundation, Gynaecology, Partnership, General manager, Cancer, National Foundation for Infectious Diseases, Research, Disease, Medical device, Human papillomavirus infection, HPV, Shijiazhuang Pharma Group, Infection, Wart, Woman, Cervical cancer, Patient, Man, Grammatical mood, Functional, Inositol, Fine chemical

FRANKFURT, Germany, Nov. 1, 2022 /PRNewswire/ -- Lo.Li. Pharma International announces the pre-launch of a new, highly anticipated product at CPHI 2022, fulfilling a latent unmet clinical need for patients with the Human Papilloma Virus (HPV). As the largest pharma industry event worldwide, CPHI Frankfurt will allow thousands of participants to have a first look at this innovative product, whose exclusive formula helps to counteract the signs, symptoms, and persistence of HPV.

Key Points: 
  • Pharma International to unveil an innovative new product at CPHI Frankfurt, which has already gained the interest of numerous distribution partners.
  • Pervistop promises to be an extremely effective tool in the management of an exceedingly unpredictable disease.
  • HPV is the most common sexually transmitted infection worldwide, and it is known to cause certain cancers and genital warts.
  • Pharma International is committed to supporting our Partners through equitable, exclusive distribution agreements, while sharing the scientific know-how and marketing strategies, which are needed to be successful.

Pervistop®, the once-daily supplement specifically designed to manage persistent HPV, is now available for exclusive distribution rights worldwide.

Retrieved on: 
星期二, 十一月 1, 2022
Marketing, EGCG, United Nations Foundation, Gynaecology, Partnership, General manager, Cancer, National Foundation for Infectious Diseases, Research, Disease, Medical device, Human papillomavirus infection, HPV, Shijiazhuang Pharma Group, Infection, Wart, Woman, Cervical cancer, Patient, Man, Grammatical mood, Functional, Inositol, Fine chemical

FRANKFURT, Germany, Nov. 1, 2022 /PRNewswire/ -- Lo.Li. Pharma International announces the pre-launch of a new, highly anticipated product at CPHI 2022, fulfilling a latent unmet clinical need for patients with the Human Papilloma Virus (HPV). As the largest pharma industry event worldwide, CPHI Frankfurt will allow thousands of participants to have a first look at this innovative product, whose exclusive formula helps to counteract the signs, symptoms, and persistence of HPV.

Key Points: 
  • Pharma International to unveil an innovative new product at CPHI Frankfurt, which has already gained the interest of numerous distribution partners.
  • Pervistop promises to be an extremely effective tool in the management of an exceedingly unpredictable disease.
  • HPV is the most common sexually transmitted infection worldwide, and it is known to cause certain cancers and genital warts.
  • Pharma International is committed to supporting our Partners through equitable, exclusive distribution agreements, while sharing the scientific know-how and marketing strategies, which are needed to be successful.

HOOKIPA announces strategic collaboration and license agreement with Roche to develop novel arenaviral immunotherapy for KRAS-mutated cancers

Retrieved on: 
星期四, 十月 20, 2022
CD8, NASDAQ, Roche, Patient, Epitope, Research, Cell, KRAS, Cancer, HIV, NEW, Arenavirus, Mutation, Gilead, Immunotherapy, Prostate cancer, GLOBE, HBV, Human papillomavirus infection, Leadership, Pharmaceutical industry, Vaccine, Antibiotics

Through the collaboration, HOOKIPA will conduct research and early clinical development through Phase 1b for HB-700, a novel investigational arenaviral immunotherapy for the treatment of KRAS-mutated cancers.

Key Points: 
  • Through the collaboration, HOOKIPA will conduct research and early clinical development through Phase 1b for HB-700, a novel investigational arenaviral immunotherapy for the treatment of KRAS-mutated cancers.
  • The agreement also includes an option for Roche to license a second arenaviral cancer immunotherapy.
  • Roche is an ideal partner, both in terms of development and reaching patients with novel cancer therapeutics.
  • HOOKIPA is collaborating with Roche on an arenaviral immunotherapeutic for KRAS-mutated cancers.

The Grand Hamdan Award goes to two scientists in Australia

Retrieved on: 
星期二, 十月 18, 2022
TRI, Immunology, Infection, Faculty of Medicine, University of Colombo, Organization, Medical research, Late, University, Faculty, Human papillomavirus infection, Center, CEO, Cervical cancer, Research, University of Queensland, Translational Research Institute, Award, HPV, Medical device, Pharmaceutical industry, Medicine

Late Dr. Jian Zhou was the Lion Principal Research Fellow, Chair HPV Structure Protein Laboratory at the Centre for Immunology and Cancer Research of the University of Queensland Faculty of Medicine, Brisbane, Australia.

Key Points: 
  • Late Dr. Jian Zhou was the Lion Principal Research Fellow, Chair HPV Structure Protein Laboratory at the Centre for Immunology and Cancer Research of the University of Queensland Faculty of Medicine, Brisbane, Australia.
  • Prof. Ian Frazer says that we could not have achieved this historic breakthrough without the contribution of Dr. Jian Zhou, who sadly passed away in 1999.
  • Sheikh Hamdan bin Rashid Al Maktoum Award for Medical Sciences is a non-profit organization that honors researchers worldwide who carry out distinguished medical research to serve humanity.
  • Also, the Award stimulates scientific interaction and enriches scientific research among doctors in the UAE and overseas.

BioVaxys Executes Binding Term Sheet for the US Marketing & Distribution for Papilocare Gel and Oral Immunocaps

Retrieved on: 
星期四, 十月 6, 2022
Women's health, IIA, FRA, CEO, OTC, Journal, Fertility, Term sheet, Severe acute respiratory syndrome coronavirus 2, Agreement, Company, Marketing, Letter of intent, IVF, World Health Organization, Clinical trial, HPV, Woman, Vaccine, Society, CSE, Cervical cancer, Menopause, OTCQB, Patient, LOI, Partnership, World, Health, Safety, Human papillomavirus infection, Cancer, Cervical, COVID-19, Birth control, Pharmaceutical industry, BC, EU

VANCOUVER, BC, Oct. 6, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") announced today that it has executed a binding Term Sheet ("Term Sheet" or "Agreement") with Procare Health Iberia, S.L. ("Procare Health"), of Barcelona, Spain ("Procare Health"), for exclusive marketing and distribution in the United States of Procare Health's leading patented product, Papilocare™, the world's first and only vaginal gel product with clinical evidences to prevent and treat HPV-dependent cervical lesions, and for Immunocaps®, an oral over-the-counter nutritional supplement that supports immune function and vaginal microbiota to help re-epithelialization of cervical lesions.  As Immunocaps® is an OTC supplement, BioVaxys anticipates that regulatory approval is not required, allowing the rapid build out of sales channels and revenue generation from the product.

Key Points: 
  • VANCOUVER, BC, Oct. 6, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF)("BioVaxys" or "Company")announced today that it has executed a binding Term Sheet ("Term Sheet" or "Agreement") with Procare Health Iberia, S.L.
  • Under the Term Sheet, BioVaxys will have responsibility for US regulatory approval for Papilocareand anticipates US registration as a Class II medical device.
  • BioVaxys has two issued US patents, and multiple US and international patent applications related to its cancer vaccines, antiviral vaccines, and diagnostic technologies.
  • BioVaxys common shares are listed on the CSE under the stock symbol "BIOV" and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB:BVAXF).

BioVaxys Executes Binding Term Sheet for the US Marketing & Distribution for Papilocare Gel and Oral Immunocaps

Retrieved on: 
星期四, 十月 6, 2022
Women's health, IIA, FRA, CEO, OTC, Journal, Fertility, Term sheet, Severe acute respiratory syndrome coronavirus 2, Agreement, Company, Marketing, Letter of intent, IVF, World Health Organization, Clinical trial, HPV, Woman, Vaccine, Society, CSE, Cervical cancer, Menopause, OTCQB, Patient, LOI, Partnership, World, Health, Safety, Human papillomavirus infection, Cancer, Cervical, COVID-19, Birth control, Pharmaceutical industry, BC, EU

VANCOUVER, BC, Oct. 6, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") announced today that it has executed a binding Term Sheet ("Term Sheet" or "Agreement") with Procare Health Iberia, S.L. ("Procare Health"), of Barcelona, Spain ("Procare Health"), for exclusive marketing and distribution in the United States of Procare Health's leading patented product, Papilocare™, the world's first and only vaginal gel product with clinical evidences to prevent and treat HPV-dependent cervical lesions, and for Immunocaps®, an oral over-the-counter nutritional supplement that supports immune function and vaginal microbiota to help re-epithelialization of cervical lesions.  As Immunocaps® is an OTC supplement, BioVaxys anticipates that regulatory approval is not required, allowing the rapid build out of sales channels and revenue generation from the product.

Key Points: 
  • VANCOUVER, BC, Oct. 6, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF)("BioVaxys" or "Company")announced today that it has executed a binding Term Sheet ("Term Sheet" or "Agreement") with Procare Health Iberia, S.L.
  • Under the Term Sheet, BioVaxys will have responsibility for US regulatory approval for Papilocareand anticipates US registration as a Class II medical device.
  • BioVaxys has two issued US patents, and multiple US and international patent applications related to its cancer vaccines, antiviral vaccines, and diagnostic technologies.
  • BioVaxys common shares are listed on the CSE under the stock symbol "BIOV" and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB:BVAXF).

Microbix Presenting Test-Workflow Validation Results at EMMD

Retrieved on: 
星期四, 十月 6, 2022
Adoption, Method, News, MDX, Pathology, TSX, VCS, Infection, Woman, RUO, Cervical cancer, Organization, Medical device, Roche, U.S. FDA, Collection, Health Canada, Human papillomavirus infection, Goal, TGA, Company, IVD, Health, Poster, OTCQX, CE, GLOBE, HPV, FDA, ISO 9001, COVID-19, Antigen, Cancer, Engineering, Vaccine

The poster presentation will be made at the 12th European Meeting on Molecular Diagnostics (EMMD) taking place in Noordwijk, Netherlands from October 12 to 14, 2022.

Key Points: 
  • The poster presentation will be made at the 12th European Meeting on Molecular Diagnostics (EMMD) taking place in Noordwijk, Netherlands from October 12 to 14, 2022.
  • The poster will be available on Microbixs website (https://microbix.com) and from EMMD after its presentation.
  • However, MDx-based screening programs require rigorous workflow design and ongoing validation to ensure their accuracy.
  • Microbix is ISO 9001 and 13485 accredited, U.S. FDA registered, Australian TGA registered, Health Canada establishment licensed, and provides CE marked products.

Cervical Cancer Diagnostics Global Market Report 2022: Increasing Prevalence of STIs Escalates Risk & Drives Growth - ResearchAndMarkets.com

Retrieved on: 
星期三, 十月 5, 2022
Biotechnology, Health, Oncology, Adoption, Colposcopy, Risk, Diagnosis, STI, Cervical cancer, CAGR, MRI, Chlamydia, Human Immunodeficiency Virus and Acquired Immune Deficiency Syndrome (Prevention and Control) Act, 2017, CT, Rectum, Cervicectomy, Blood, Awareness, Immunotherapy, Gonorrhea, HIV/AIDS, HPV, PET, Cervical, Smoker, Syphilis, Human papillomavirus infection, COVID-19, Magnetic resonance imaging, Medical imaging, Growth

The "Cervical Cancer Diagnostics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cervical Cancer Diagnostics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
  • The global cervical cancer diagnostics market size reached US$ 7.1 Billion in 2021.
  • Looking forward, the publisher expects the market to reach US$ 9.9 Billion by 2027, exhibiting a CAGR of 5.7% during 2021-2027.
  • Moreover, the growing emphasis on developing low-cost and efficient testing products is anticipated to fuel the market growth.